Viewing Study NCT02684292


Ignite Creation Date: 2025-12-24 @ 3:30 PM
Ignite Modification Date: 2026-01-04 @ 2:53 AM
Study NCT ID: NCT02684292
Status: COMPLETED
Last Update Posted: 2025-12-23
First Post: 2016-02-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module